

**COSENTYX (SECUKINUMAB)
(PREFERRED)
PRIOR AUTHORIZATION FORM**
(form effective 1/1/20)



Keystone First

PERFORMRxSM
Next Generation Pharmacy Benefits

Fax to PerformRxSM at **1-215-937-5018**, or to speak to a representative call **1-800-588-6767**.

PRIOR AUTHORIZATION REQUEST INFORMATION			
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	# of pages:	Name of office contact:
Contact's phone number:		LTC facility contact/phone:	
PATIENT INFORMATION			
Patient name:		Patient ID #:	DOB:
Street address:		Apt. #:	City/state/zip:
PRESCRIBER INFORMATION			
Prescriber name:		Specialty:	
State license #:	NPI:	MA Provider ID #:	
Street address:		Suite #:	City/state/zip:
Phone:		Fax:	
CLINICAL INFORMATION			
Product requested: <input type="checkbox"/> Cosentyx 300 mg dose - 2 pens <input type="checkbox"/> Cosentyx 300 mg dose - 2 syringes <input type="checkbox"/> Cosentyx _____			
Dose/directions:			
Quantity:	Refills:	Patient weight:	
Diagnosis (<i>submit documentation</i>):		Dx code (<i>required</i>):	
PHARMACY INFORMATION (PRESCRIBER TO IDENTIFY THE PHARMACY THAT IS TO DISPENSE THE MEDICATION):			
Deliver to: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Physician's Office <input type="checkbox"/> Patient's Preferred Pharmacy Name:			
Pharmacy Phone #:		Pharmacy Fax #:	
<input type="checkbox"/> I acknowledge that the patient agrees with the pharmacy chosen for delivery of this medication.			
INITIAL REQUESTS - COMPLETE SECTIONS APPLICABLE TO PATIENT'S DIAGNOSIS			
1. All diagnoses: Check all that apply to the patient and <i>submit documentation for each</i> . <input type="checkbox"/> vaccinated for hepatitis B <input type="checkbox"/> screened for hepatitis B (surface antigen and core antibody) <input type="checkbox"/> up-to-date with all age-appropriate immunizations <input type="checkbox"/> screened for tuberculosis			
2. All diagnoses: Does the patient have a history of trial and failure, contraindication, or intolerance to the preferred agent, Humira? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation of clinical response.</i>			
3. Ankylosing spondylitis or psoriatic arthritis: Does the patient have a history of trial and failure, contraindication, or intolerance of the following? <input type="checkbox"/> four-week trial each of at least 2 different NSAIDs <input type="checkbox"/> eight-week trial of methotrexate or other DMARD (does not apply to axial disease) <input type="checkbox"/> Yes – List medications tried: _____ <input type="checkbox"/> No			
4. Plaque psoriasis: Does at least one of the following apply to the patient? <input type="checkbox"/> at least 5% of the body surface area (BSA) is affected <input type="checkbox"/> critical areas of the body are involved (face, palms, soles of feet, and/or genitals) <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation of clinical response.</i>			
5. Plaque psoriasis: Does the patient have a history of trial and failure, contraindication, or intolerance of a 3-month trial of phototherapy? Check all that apply. <input type="checkbox"/> PUVA <input type="checkbox"/> UVB light <input type="checkbox"/> other: _____ <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation of all treatments tried and outcomes.</i>			
6. Plaque psoriasis: Does the patient have a history of trial and failure, contraindication, or intolerance of the following medications? Check all that apply. <input type="checkbox"/> acitretin <input type="checkbox"/> cyclosporine <input type="checkbox"/> methotrexate <input type="checkbox"/> Yes – List medications tried: _____ <input type="checkbox"/> No			
RENEWAL REQUESTS			
1. Since starting Cosentyx, did the patient experience a positive clinical response and/or improved level of functioning? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation of clinical response.</i>			
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION			
Prescriber signature:			Date:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.